Sensory Neuropathy Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Peripheral Neuropathy (Sensory Neuropathy) – Pipeline Review, H1 2015” report to its store. The report provides an overview of the peripheral neuropathy (sensory neuropathy)’s therapeutic pipeline.

Sensory Neuropathy Therapeutics Pipeline Market

Sensory Neuropathy Therapeutics Pipeline Market

The report “Peripheral Neuropathy (Sensory Neuropathy) – Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Peripheral Neuropathy (Sensory Neuropathy) is a damage to one or more of peripheral nerves that includes motor, sensory and autonomic fibers. The cause of peripheral neuropathy is often unidentified. The most widespread causes of peripheral neuropathy are diabetes, shingles, kidney failure, various drugs and vitamin shortage. When the peripheral sensory nerves are damaged, they fail to send sensory messages (pain, heat, touch, cold etc). Neuropathy occurs in 60% to 70% of people with diabetes. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/peripheral-neuropathy-sensory-neuropathy-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and special features on late-stage and discontinued projects. Companies discussed in this Peripheral Neuropathy (Sensory Neuropathy) – Pipeline Review, H1 2015 report include Acorda Therapeutics, Inc., aTyr Pharma, Inc., GeNeuro SA, INSYS Therapeutics, Inc., Mitsubishi Tanabe Pharma Corporation, Neuren Pharmaceuticals Limited, Pfizer Inc., RegeneRx Biopharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited.

Symptoms of peripheral neuropathy (sensory neuropathy) includes burning pain, excessive sensitivity to touch, loss of balance and coordination, regular numbness and tingling in the hands or feet and impaired capability to sense the location of one’s limbs. Drug profiles discussed in this report includes cannabidiol, fingolimod hydrochloride, GL-2045, immune globulin, immune globulin (human), Monoclonal Antibody for CIDP, NNZ-2591, NP-1998, NRP-2945, Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma, Peptides for Neuropathic Pain and Peripheral Neuropathy, Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma, Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder, RGN-352, Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis, Small Molecules to Inhibit Cysteine Protease and Caspases for Oncology, Immunology, Infectious and CNS Disorders, Synthetic Peptides for Peripheral Neuropathy. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269576 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this “Peripheral Neuropathy (Sensory Neuropathy) – Pipeline Review, H1 2015” report include: Jul 12, 2013: Neuren Receives Notice of Allowance for New Patent.

Table of content

List of Tables
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H1 2015
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Acorda Therapeutics, Inc., H1 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by aTyr Pharma, Inc., H1 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by GeNeuro SA, H1 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by INSYS Therapeutics, Inc., H1 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Neuren Pharmaceuticals Limited, H1 2015 24
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Pfizer Inc., H1 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Teijin Pharma Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Recent Pipeline Updates, H1 2015
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects, H1 2015
Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products, H1 2015

Explore more reports on Central Nervous System (CNS) therapeutics Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/central-nervous-system-cns-therapeutics .

About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@chinamrreport
Follow >
Market Reports China
Like >
Follow us on
Visit website